2023
New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events
Micevic G, Daniels A, Flavell R. New insights into programmed cell death protein 1 blockade-associated cutaneous immune-related adverse events. British Journal Of Dermatology 2023, 189: 355-357. PMID: 37471669, PMCID: PMC10503525, DOI: 10.1093/bjd/ljad236.Peer-Reviewed Original ResearchConceptsCutaneous immune-related adverse eventsImmune-related adverse eventsSelf-reactive T cellsCheckpoint receptor PD-1PD-1 inhibitorsHalf of patientsImmune checkpoint blockadeAntitumor immune responseReceptor PD-1Adverse eventsCheckpoint blockadePD-1Immune toleranceCTLA-4T cellsImmune responseLandmark studiesMolecular mechanismsFunctional roleCritical functional rolePatientsBlockadeDermatologistsImportant clues
2022
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Talty R, Micevic G, Wang A, Ko CJ, Damsky W. Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist. Case Reports In Dermatology 2022, 14: 214-218. PMID: 36158852, PMCID: PMC9459519, DOI: 10.1159/000525894.Peer-Reviewed Original ResearchRestless legs syndromeRotigotine patchTransdermal patchRotigotine transdermal patchTransdermal dopamine agonistsPotential side effectsAbsence of melanocytesDopamine agonismSystemic medicationsTopical medicationsDopamine agonistsLegs syndromeCase reportHistopathologic examinationDermal-epidermal junctionAnterior shoulderPharmacologic substancesSide effectsPatch applicationPotential mechanismsLeukodermaMedicationsPatientsSyndromeAgonists
2018
PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival
Micevic G, Thakral D, McGeary M, Bosenberg M. PD‐L1 methylation regulates PD‐L1 expression and is associated with melanoma survival. Pigment Cell & Melanoma Research 2018, 32: 435-440. PMID: 30343532, PMCID: PMC6475614, DOI: 10.1111/pcmr.12745.Peer-Reviewed Original ResearchConceptsPD-L1 expressionDNA methylationPD-1/PD-L1 immune checkpointIndependent survival prognostic factorPD-L1 promoter methylationPD-L1 immune checkpointSurvival prognostic factorsPD-L1 promoterPromoter DNA methylationOverall survivalImmune checkpointsPrognostic factorsMelanoma patientsMelanoma survivalEpigenetic mechanismsTranscriptional phenotypeClinical importanceMelanomaCpG lociMethylationPromoter methylationSurvivalTherapeutic applicationsExpressionPatients
2016
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors
Brooks ED, Schoenhals JE, Tang C, Micevic G, Gomez DR, Chang JY, Welsh JW. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. The Cancer Journal 2016, 22: 257-266. PMID: 27441745, PMCID: PMC5812885, DOI: 10.1097/ppo.0000000000000210.Peer-Reviewed Original ResearchConceptsStereotactic ablative radiation therapyImmune checkpoint therapyAblative radiation therapyRadiation therapyNovel therapeuticsImmune checkpoint inhibitionImmune checkpoint inhibitorsLocal treatment optionsEncouraging clinical responsesClinical responseExperience relapseSystemic therapyTreatment optionsClinical studiesLocal irradiationSystemic effectsImmunogenic effectsImmunotherapySolid tumorsTherapyNumerous cancersTumorsTherapeuticsRelapsePatients